

## Zafgen Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 27-Apr-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

    Phase 3 Clinical..... 11

    Discovery..... 16

[Return to Table of Contents](#)

# Zafgen Inc

## COMPANY OVERVIEW

Company Name	Zafgen Inc
Parent Company Name	Zafgen Inc
Website	<a href="http://www.zafgen.com/">http://www.zafgen.com/</a>
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	3
Number of Patents as Owner	33
Number of Patents as Third Party	0
Number of Deals	3
Key Indications	Obesity,Non-insulin dependent diabetes,Non-alcoholic steatohepatitis,Brain tumor,Non alcoholic fatty liver disease,Prader-Willi syndrome,Weight gain,Weight loss,Alzheimers disease,Angiogenesis disorder,Cardiovascular disease,Stroke
Key Target-based Actions	Methionine aminopeptidase-2 inhibitor,C-reactive protein inhibitor,Thioredoxin stimulator,Methionine aminopeptidase-2 modulator
Key Technologies	Small molecule therapeutic,Oral formulation,Subcutaneous formulation,Natural product,Crystalline form,Intravenous formulation,Formulation preservation,Oligonucleotide antisense

## COMPANY PROFILE

### SUMMARY

Zafgen, found in 2005, is a private venture-backed biopharmaceutical company that develops obesity therapeutics based on vascular targeting in adipose tissue.

### COMPANY LOCATION

The company is based in Cambridge, MA.

### LICENSING AGREEMENTS

In January 2009, Argenta Discovery and Zafgen signed an agreement to research and discover therapeutics for the treatment of obesity.

In August 2008, Anthill and Zafgen entered into an agreement where Anthill was to use its ACOS high-speed synthesis and purification capabilities to assist Zafgen in lead compounds identification for its obesity programs.

### FINANCIAL

In January 2015, the company commenced an underwritten public offering of 2,840,909 shares of its common stock. The underwriters were to be granted a 30-day option to purchase up to an additional 426,136 shares of common stock. Later that month, Zafgen priced the offering of 3,942,200 common stock shares at a price of \$35 each, which includes the underwriters' option to purchase up to an additional 514,200 common stock shares at the public offering price. The offering was expected to close on or about January 28, 2015. Later that month, the offering was closed.

In December 2014, Zafgen was selected for addition to the NASDAQ Biotechnology Index.

In June 2014, Zafgen announced an IPO of 6,000,000 shares of its common stock priced at \$16 per share. At that time, underwriters were granted a 30-day option to purchase up to an additional 900,000 shares of common stock to cover any over-allotments. The shares were traded on the NASDAQ Global Market under the ticker symbol "ZFGN". Later that month, the offering was closed and at that time, the over-allotment option was fully exercised.

In April 2014, the company closed \$20 million term loan with Oxford Finance LLC and MidCap Financial.

[Return to Table of Contents](#)



In December 2013, Zafgen raised \$45 million in a series E equity financing round.

In December 2012, Zafgen raised \$21 million in a series D equity financing.


In July 2011, Zafgen raised \$33 million in a series C financing.

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Nutritional disorder	3	3	6
Gastrointestinal disease	2	1	3
Metabolic disorder	2	1	3
Endocrine disease	2	1	3
Inflammatory disease	1	0	1
Neoplasm	1	0	1
Neurological disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	2
No Development Reported	3

[Return to Table of Contents](#)

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	0	0	1	0	1
Technology - Target Validation	0	0	1	0	1

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Nutritional disorder	2	8
Metabolic disorder	1	1
Endocrine disease	1	1
Gastrointestinal disease	1	1

### Trials by Phase

Phase	Ongoing	All
Phase 3	1	1
Phase 2	1	4
Phase 1	0	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	7	0	7
Endocrine disease	4	0	4
Gastrointestinal disease	5	0	5
Genitourinary disease	4	0	4

[Return to Table of Contents](#)





Growth disorder	1	0	1
Hematological disease	1	0	1
Degeneration	3	0	3
Andrology	1	0	1
Immune disorder	1	0	1
Psychiatric disorder	2	0	2
Musculoskeletal disease	4	0	4
Neoplasm	2	0	2
Ocular disease	1	0	1
Genetic disorder	1	0	1
Metabolic disorder	6	0	6
Mouth disease	1	0	1
Neurological disease	4	0	4
Nutritional disorder	25	0	25
Respiratory disease	1	0	1
Infectious disease	2	0	2
Injury	2	0	2
Inflammatory disease	3	0	3
Fatigue	1	0	1
Gynecology and obstetrics	1	0	1
Dermatological disease	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen

#### beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen SNAPSHOT

<b>Drug Name</b>	beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen
<b>Key Synonyms</b>	beloranib
<b>Originator Company</b>	Chong Kun Dang Pharmaceutical Corp
<b>Active Companies</b>	Zafgen Inc
<b>Inactive Companies</b>	Chong Kun Dang Pharmaceutical Corp
<b>Highest Status</b>	Phase 3 Clinical
<b>Active Indications</b>	Obesity;Brain tumor;Prader-Willi syndrome;Non-insulin dependent diabetes
<b>Target-based Actions</b>	Methionine aminopeptidase-2 inhibitor
<b>Other Actions</b>	Lipid metabolism modulator;Hypoglycemic agent;Anticancer
<b>Technologies</b>	Small molecule therapeutic;Subcutaneous formulation
<b>Last Change Date</b>	20-Apr-2015

#### beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen DEVELOPMENT PROFILE

##### SUMMARY

Zafgen, under license from Chong Kun Dang (CKD) Pharmaceutical, is developing ZGN-440, an twice-weekly sc injectable formulation of the methionine aminopeptidase 2 (MetAP2) inhibitor beloranib, for the potential treatment of obesity, Prader-Willi syndrome, craniopharyngioma and type II diabetes,,. In October 2014, a phase III trial for Prader-Willi syndrome began. In June 2014, a phase IIa trial for craniopharyngioma-associated obesity was initiated ; in January 2015, data were reported. In December 2014, a phase IIb trial for severe obesity and type II diabetes was initiated.

#### beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Zafgen Inc	Prader-Willi syndrome	US	Phase 3 Clinical	30-Sep-2014
Zafgen Inc	Brain tumor	US	Phase 2 Clinical	31-Mar-2014
Zafgen Inc	Non-insulin dependent diabetes	Australia	Phase 2 Clinical	15-Dec-2014
Zafgen Inc	Obesity	Australia	Phase 2 Clinical	30-Aug-2012

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Zafgen Inc	Prader-Willi syndrome	Europe	Discovery	13-May-2014
Chong Kun Dang Pharmaceutical Corp	Obesity	US	Discontinued	06-Nov-2008

### beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
251111-30-5	2
	
Name	Type
beloranib	INN

### beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen DRUG NAMES

Names	Type
beloranib	INN
beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen	
ZGN-440	Research Code
beloranib (sc, obesity), Zafgen	

### beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Obesity											
0	0	0	0	1	3	0	1	0	0	1	4
Prader-Willi syndrome											
0	0	1	1	0	1	0	0	0	0	1	2

[Return to Table of Contents](#)

Non-insulin dependent diabetes											
0	0	0	0	1	1	0	0	0	0	1	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	1	1	4	0	1	0	0	2	6


### Phase Definitions

<b>Phase 3 Clinical</b> Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)	
<b>Phase 2 Clinical</b> Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)	
<b>Phase 1 Clinical</b> Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0	

## beloranib (sc, obesity/Prader-Willi syndrome/craniopharyngioma ), Zafgen DEALS AND PATENTS

### DEALS


#### Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Chong Kun Dang Pharmaceutical Corp	1	0	0	0	1
Zafgen Inc	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Zafgen Inc	7	0	7

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	6
Product (derivative)	1
Formulation	1

[Return to Table of Contents](#)

## second generation beloranib (obesity), Zafgen

### second generation beloranib (obesity), Zafgen SNAPSHOT

Drug Name	second generation beloranib (obesity), Zafgen
Key Synonyms	beloranib
Originator Company	Zafgen Inc
Active Companies	Zafgen Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Obesity
Target-based Actions	Methionine aminopeptidase-2 inhibitor
Other Actions	
Technologies	Small molecule therapeutic;Subcutaneous formulation
Last Change Date	20-Apr-2015

### second generation beloranib (obesity), Zafgen DEVELOPMENT PROFILE

#### SUMMARY

Zafgen is investigating second generation compounds to beloranib, as methionine aminopeptidase 2 (MetAP2) inhibitors, for the potential sc treatment of obesity. In March 2014, the drug was listed as being in preclinical development. At that time, the company expected filing an IND in 2015. In April 2015, the IND was expected to be filed in the first quarter of 2016.

### second generation beloranib (obesity), Zafgen DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Zafgen Inc	Obesity	US	Discovery	31-Mar-2014

### second generation beloranib (obesity), Zafgen CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
251111-30-5	2
	
Name	Type
beloranib	INN

### second generation beloranib (obesity), Zafgen DRUG NAMES

Names	Type
beloranib	INN
second generation MetAP2 inhibitor (sc, obesity), Zafgen	
second generation beloranib (obesity), Zafgen	

[Return to Table of Contents](#)

## ZGN-839

### ZGN-839 SNAPSHOT

Drug Name	ZGN-839
Key Synonyms	
Originator Company	Zafgen Inc
Active Companies	Zafgen Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Non-insulin dependent diabetes;Non alcoholic fatty liver disease;Non-alcoholic steatohepatitis;Obesity
Target-based Actions	Methionine aminopeptidase-2 inhibitor
Other Actions	Hypoglycemic agent;Anti-inflammatory
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	20-Mar-2015

### ZGN-839 DEVELOPMENT PROFILE

#### SUMMARY

Zafgen is investigating ZGN-839 (ZAF-839), a methionine aminopeptidase 2 (MetAP2) inhibitor, for the potential oral treatment of type 2 diabetes, non-alcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease and abdominal obesity,. By April 2014, preclinical development was underway for all four indications. At that time, IND-enabling studies were planned for 2014, and an IND was to be filed in 1H15.

### ZGN-839 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Zafgen Inc	Non alcoholic fatty liver disease	US	Discovery	18-Apr-2014
Zafgen Inc	Non-alcoholic steatohepatitis	US	Discovery	31-Mar-2014
Zafgen Inc	Non-insulin dependent diabetes	US	Discovery	31-Mar-2014
Zafgen Inc	Obesity	US	Discovery	18-Apr-2014

[Return to Table of Contents](#)



**ZGN-839 DRUG NAMES**

Names	Type
ZGN-839	Research Code
ZAF-839	Research Code
methionine aminopeptidase 2 inhibitor (oral, non-alcoholic steatohepatitis/type 2 diabetes mellitus), Zafgen	

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

